Pfizer Banking On China's Emerging Neuropathic Pain Market For Lyrica
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Pfizer Inc. has high expectations for its neuropathic pain blockbuster Lyrica (pregabalin) in China with its initial indication for post-herpetic neuralgia (PHN), but patient education will be key as neuropathic pain is not widely known within China
You may also be interested in...
Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)
[Editor's note: This is part two of a two-part story; part one appeared in PharmAsia News, March 4, 2011.]
Pfizer, Roche, AstraZeneca: Emerging Markets Earnings Roundup (Part 3)
Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.
AstraZeneca, Pfizer, GlaxoSmithKline: Emerging Markets Earnings Roundup (Part 2 of 2)
Restructuring and diversification was the theme of third quarter earnings calls, as both American and European Big Pharma companies continued to shift resources into emerging markets. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights. Part one covered analysis of Eli Lilly, J&J and Novartis.